These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7107578)

  • 21. Bovine antithrombin-III: miscellaneous observations.
    Seegers WH; Novoa E; Andary TJ; Hassouna HI
    Thromb Res; 1977 Dec; 11(6):809-15. PubMed ID: 601751
    [No Abstract]   [Full Text] [Related]  

  • 22. The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin.
    Björk I; Jackson CM; Jörnvall H; Lavine KK; Nordling K; Salsgiver WJ
    J Biol Chem; 1982 Mar; 257(5):2406-11. PubMed ID: 6977539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.
    Bray B; Lane DA; Freyssinet JM; Pejler G; Lindahl U
    Biochem J; 1989 Aug; 262(1):225-32. PubMed ID: 2818566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in the effect of antithrombin on thrombin clotting and thrombin esterase activity.
    Gans H; Boulton A
    Thromb Diath Haemorrh; 1969 Aug; 22(1):28-31. PubMed ID: 5821245
    [No Abstract]   [Full Text] [Related]  

  • 25. Lysine-heparin interactions in antithrombin. Properties of K125M and K290M,K294M,K297M variants.
    Fan B; Turko IV; Gettins PG
    Biochemistry; 1994 Nov; 33(47):14156-61. PubMed ID: 7947827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of heparin modification on its activity in enhancing the inhibition of thrombin by antithrombin III.
    Danishefsky I; Ahrens M; Klein S
    Biochim Biophys Acta; 1977 Jun; 498(1):215-22. PubMed ID: 560216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II.
    Becker DL; Fredenburgh JC; Stafford AR; Weitz JI
    J Biol Chem; 1999 Mar; 274(10):6226-33. PubMed ID: 10037709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombin III and heparin.
    Barrowcliffe TW; Johnson EA; Thomas D
    Br Med Bull; 1978 May; 34(2):143-50. PubMed ID: 350337
    [No Abstract]   [Full Text] [Related]  

  • 29. Reaction of antithrombin with proteases. Nature of the reaction with trypsin.
    Wong RF; Chang TL; Feinman RD
    Biochemistry; 1982 Jan; 21(1):6-12. PubMed ID: 7059581
    [No Abstract]   [Full Text] [Related]  

  • 30. Actions and interactions of antithrombin and heparin.
    Rosenberg RD
    N Engl J Med; 1975 Jan; 292(3):146-51. PubMed ID: 127943
    [No Abstract]   [Full Text] [Related]  

  • 31. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement.
    Olson ST; Björk I; Sheffer R; Craig PA; Shore JD; Choay J
    J Biol Chem; 1992 Jun; 267(18):12528-38. PubMed ID: 1618758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A disulfide bond in antithrombin is required for heparin-accelerated thrombin inactivation.
    Longas MO; Ferguson WS; Finlay TH
    J Biol Chem; 1980 Apr; 255(8):3436-41. PubMed ID: 7364749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Routes of thrombin action in the production of proteolytically modified, secondary forms of antithrombin-thrombin complex.
    Fish WW; Orre K; Björk I
    Eur J Biochem; 1979 Nov; 101(1):39-44. PubMed ID: 510313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Purification and characterization of rat plasma antithrombin III.
    Takahara H; Sinohara H
    Biochim Biophys Acta; 1980 Mar; 612(1):185-94. PubMed ID: 7362830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of immunochemical and biological properties of human anti thrombin during blood clotting and upon interaction with exogenous thrombin.
    Esnard F; Gauthier F; Mouray H
    Thromb Res; 1983 Jul; 31(1):127-33. PubMed ID: 6612691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of collagen on thrombin inactivation by antithrombin-III and heparin.
    Blaskó G; Bédi J; Machovich R; Pálos LA
    Haematologia (Budap); 1977; 11(1-2):163-8. PubMed ID: 615087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of antithrombin III microheterogeneity by isoelectric focusing in polyacrylamide gels and immunoblotting.
    Daly M; Hallinan F
    Thromb Res; 1985 Oct; 40(2):207-14. PubMed ID: 4071470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of heparin on factor XIa and plasmin.
    Rosenberg RD
    Thromb Diath Haemorrh; 1975 Feb; 33(1):51-62. PubMed ID: 235160
    [No Abstract]   [Full Text] [Related]  

  • 40. The antithrombin P1 residue is important for target proteinase specificity but not for heparin activation of the serpin. Characterization of P1 antithrombin variants with altered proteinase specificity but normal heparin activation.
    Chuang YJ; Swanson R; Raja SM; Bock SC; Olson ST
    Biochemistry; 2001 Jun; 40(22):6670-9. PubMed ID: 11380262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.